IDEAYA pipeline advances with darovasertib NDA nearing submission
IDEAYA Biosciences says its precision oncology pipeline is advancing, led by darovasertib nearing NDA submission and multiple phase III trials, alongside DLL3 ADC and MTAP/KRAS programs.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.